In human lung cancer, group 3 ILCs (ILC3s) were found to contribute to antitumor immunity by supporting the formation of the tertiary lymphoid structure (TLS) composed of a network of CD21+ follicular dendritic cells surrounded by T cells and CD21+ B cells through the expression of TNF-α, LTα, and LTβ [203]. This evidence concerns the gene CR2 and lung carcinoma.